新天药业(002873) - 2021 Q2 - 季度财报

Financial Performance - The company's operating revenue for the first half of 2021 was CNY 454,031,233.06, representing a 49.91% increase compared to CNY 302,862,307.16 in the same period last year[20]. - The net profit attributable to shareholders of the listed company reached CNY 46,837,320.12, an increase of 85.83% from CNY 25,204,359.22 year-on-year[20]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 46,590,801.43, up 90.36% from CNY 24,475,388.50 in the previous year[20]. - The basic earnings per share increased to CNY 0.4100, an 86.96% rise from CNY 0.2193 in the same period last year[20]. - The diluted earnings per share were CNY 0.3811, reflecting an increase of 84.37% compared to CNY 0.2067 in the previous year[20]. - The weighted average return on equity was 5.57%, up from 3.41% in the same period last year, an increase of 2.16%[20]. - The company reported a significant increase in financial expenses, which rose by 554.25% to ¥8,208,493.53, primarily due to increased loan interest and reduced government subsidies[54]. - The company reported a net profit of 4,659.08 million yuan for the current period, representing a 90.36% increase compared to the same period last year[154]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,534,079,519.74, a slight decrease of 0.12% from CNY 1,535,933,766.56 at the end of the previous year[20]. - The total liabilities decreased to 481,262,685.67 yuan from 513,639,094.28 yuan in the previous year[160]. - The company's total assets at the end of the reporting period amounted to 1,190 million yuan, showing a growth from the previous period's total assets of 1,313.8 million yuan[188]. - The total liabilities at the end of the reporting period were 373.89 million yuan, a decrease from 846.22 million yuan in the previous period, indicating a reduction of approximately 56%[188]. Cash Flow - The net cash flow from operating activities was CNY 59,736,164.46, showing a decrease of 3.00% compared to CNY 61,586,412.45 in the same period last year[20]. - The net cash flow from investment activities improved by 102.66%, reaching ¥5,672,551.43, mainly due to the maturity of financial products[54]. - The net cash flow from operating activities generated a net amount of CNY 59,736,164.46, slightly down from CNY 61,586,412.45 in the first half of 2020[177]. - The total cash and cash equivalents at the end of the period stood at ¥234,174,509.64, down from ¥245,929,798.90 at the end of the previous period, indicating a decrease in liquidity[182]. Research and Development - The company focuses on the research, development, production, and sales of traditional Chinese medicine, with a product line that includes eight dosage forms and two production lines for traditional Chinese medicine pieces[28]. - Research and development investment amounted to ¥11,889,702.71, reflecting a 5.25% increase from ¥11,296,412.99, indicating continued commitment to innovation[54]. - The company emphasizes a strategy of "producing one generation, reserving one generation, and developing one generation" for its R&D efforts[36]. - The company has three new traditional Chinese medicine products that have completed Phase III clinical trials and 445 varieties of traditional Chinese medicine formula granules in clinical research[36]. Market and Sales - The company aims to leverage its brand advantage to enhance market promotion of its exclusive products and attract top talent for technological innovation[46]. - The marketing strategy emphasizes professional academic promotion, enhancing product visibility and trust among healthcare professionals through various academic forums and clinical trials[40]. - Gynecology products generated ¥323,202,853.44, making up 71.19% of total revenue, with a significant increase of 55.66% year-on-year[56]. - The company has established a strong market presence with its leading products, including Kuntai capsules and Ningpitai capsules, achieving over ¥100 million in market scale for several key products[46]. Environmental Compliance - The company has two wastewater treatment plants, with the old plant having a daily processing capacity of 2,000 tons and the new plant 720 tons[84]. - The wastewater treatment process for the old plant includes UASB, biological contact oxidation, and two-stage filtration, ensuring compliance with discharge standards[84]. - The company has obtained pollution discharge permits for both old and new plants, with the old plant's permit valid until June 28, 2023, and the new plant's until May 24, 2025[87]. - The company reported no exceedances in pollutant emissions for COD and ammonia nitrogen at both plants[83]. Shareholder and Equity Information - The company plans to distribute 4 additional shares for every 10 shares held, using capital reserves, with no cash dividends proposed[4]. - The company has allocated 15,021,170.80 yuan for share repurchase during the reporting period, with total cash dividends amounting to 15,021,170.80 yuan, accounting for 100% of the distributable profit[77]. - The total number of ordinary shareholders at the end of the reporting period was 11,954[132]. - The largest shareholder, Guiyang Xintian Biological Technology Development Co., Ltd., holds 38.89% of the shares, with a reduction of 6 million shares during the reporting period[132]. Corporate Governance - The company has not experienced any changes in its board of directors, supervisors, or senior management during the reporting period[76]. - The company emphasizes the protection of investor rights and has established a reasonable dividend plan to actively return profits to shareholders[92]. - The company has not reported any significant litigation or arbitration matters during the reporting period[101].